NYXH Nyxoah SA

$NYXH I’ve been watching the Stock for years. I’m in my first purchase Friday at the close. We need to get market exposure to finally get moving again

Latest company news, October 15, 2026: Nyxoah presented full 12-month ACCCESS data in complete concentric collapse patients at ISSS 2026: 77.2% AHI responder rate, 74.3% median AHI reduction (per-protocol), no device- or procedure-related serious adverse events. It also submitted a PMA supplement asking the FDA to extend Genio to these patients. $NYXH Details on our site. Not investment advice.

$NYXH Such great news, but market has no reaction! Unbelievable!! CCC patients are contraindicated by Inspire device. This is huge for Genio!

$NYXH Picked up a bunch at $.80 last week. Added more at $.95 today. I think the ER will be positive and show momentum commercially.

$NYXH Many people do not realize how big the deal is to have CCC indication for Genio device. This stock is so unbelievably undervalued. I have loaded a lot more today.

$NYXH I just listened to the conference call. The company is flying under Wall Street’s radar, which was clear when only 1 analyst dialed into the conference call. Overall I like what I hear and have strong conviction in this company. 1) Genio is new technology direct rival to Inspire V, TAM is $10B in USA alone ( Genio and Inspire V) 2) market adoption is robust considering it’s on initial stage of launch. 3) CCC PMA is expected to approve in Q1 2027 which targets 1 in 4 patients excluded by Inspire 4) Reimbursement is good 5)Liam Kelly seems to know exactly what he is doing/should do. Maybe buy some NYXH stocks next to prove he has high conviction. 6) my only concern is cash burn rate is high, but new product launch is always expensive. And Liam is fully aware and taking action. I hope I am right as I have accumulated lots of shares. At this price, I feel like a kid in a candy store 😀

$NYXH might as well sell to $INSP . Not that I think inspire would buy since their technology is 100x better and NYXH is going bankrupt.

$NYXH Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.20 up 72.97% YoY • Reported revenue of $10.39M up 349.78% YoY • Nyxoah expects to continue ramping up sales primarily in the United States; it strives for further growth in Germany, Switzerland, the United Kingdom, the Middle East and select international markets, subject to favourable reimbursement.

$NYXH — Q3 results on 5 Nov; call at 16:30 ET. Information only — not investment advice. More details in our hub.

$NYXH announced preliminary financial and operating results for Q3 2026 in a Form 6-K filing.

Latest company news, October 19, 2026: Nyxoah reported preliminary Q3 revenue of about EUR 9.2M (19% sequential growth) and lowered 2026 revenue guidance to EUR 33-35M from EUR 36-40M. Figures are preliminary and unaudited. Nyxoah ($NYXH) Stock Hub: Genio, ACCCESS, Cash, Dilution Deeper dive in our hub. Not investment advice.